Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Shortiz10on Apr 02, 2024 2:49pm
349 Views
Post# 35965779

This is why they are being sued

This is why they are being suedI had a hard time finding the reason Antibe is being sued by Nuance Pharma.

From Steetwise reports https://www.streetwisereports.com/article/2023/06/30/biotech-co-remains-opportunity-for-those-with-high-risk-tolerance.html

Nuance Pharma is seeking to rescind their license agreement with Antibe Pharmaceuticals due to allegations that Antibe failed to adequately disclose information regarding the risks associated with transaminase elevations linked to otenaproxesul, which is a drug covered by the agreement. Nuance alleges that this lack of disclosure constitutes a breach of the agreement. Despite these claims, analysts believe it's unlikely that Antibe will have to return the upfront payment as the risks of potential side-effects were well-known. Antibe completed an arbitration proceeding with Nuance in May and expects the decision in the future.

In case you're wondering:
Transaminase elevations refer to higher than normal levels of certain enzymes in the blood, specifically alanine transaminase (ALT) and aspartate transaminase (AST). These enzymes are typically found within liver cells, and when the liver is damaged or inflamed, they can leak into the bloodstream, causing elevated levels. So, transaminase elevations often indicate liver damage or liver disease.

We all now know the outcome:
https://markets.ft.com/data/announce/detail?dockey=600-202404010700BIZWIRE_USPRX____20240401_BW046957-1
 
<< Previous
Bullboard Posts
Next >>